Full Press Release Details
New Analyses of Sotagliflozin Showing Time to Clinical Benefit Presented at The American College of Cardiology's 72nd Annual Scientific Session Together With World Heart Federation's World Congress of Cardiology.
LXRX
New Analyses of Sotagliflozin Showing Time to Clinical Benefit Presented at The American College of Cardiology's 72nd Annual Scientific Session Together With World Heart Federation's World Congress of Cardiology
Key Takeaway: New Analyses of Sotagliflozin Showing Time to Clinical Benefit Presented at The American College of Cardiology's 72nd Annual Scientific Session Together With World Heart Federation's World Congress of Cardiology
Price reaction · baseline $2.68 (2023-03-03 close) · hit after-hours · clean, no other LXRX news in the window
day 0 close
-3%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+111%
120-day peak, hindsight
Typical move
11%
average across 13 past catalysts
Cash runway
~61 mo
Minimal dilution risk
Lead asset
Sotagliflozin
Phase 3 · Type 1 Diabetes Mellitus